These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 32947651

  • 1. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
    Zucca E, Cascione L, Ruberto T, Facchinelli D, Schär S, Hayoz S, Dirnhofer S, Giovanella L, Bargetzi M, Mamot C, Ceriani L.
    Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
    [Abstract] [Full Text] [Related]

  • 2. Prognostic Value of 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen.
    Michaud L, Bantilan K, Mauguen A, Moskowitz CH, Zelenetz AD, Schöder H.
    J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY, Guo Z, Sun J, Yang WP, Li TR.
    Zhonghua Zhong Liu Za Zhi; 2018 Jul 23; 40(7):528-533. PubMed ID: 30060362
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis.
    Ceriani L, Milan L, Cascione L, Gritti G, Dalmasso F, Esposito F, Pirosa MC, Schär S, Bruno A, Dirnhofer S, Giovanella L, Hayoz S, Mamot C, Rambaldi A, Chauvie S, Zucca E.
    Hematol Oncol; 2022 Feb 23; 40(1):11-21. PubMed ID: 34714558
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Metabolic tumour area: a novel prognostic indicator based on 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma in the R-CHOP era.
    Cui S, Xin W, Wang F, Shao X, Shao X, Niu R, Zhang F, Shi Y, Liu B, Gu W, Wang Y.
    BMC Cancer; 2024 Jul 25; 24(1):895. PubMed ID: 39054508
    [Abstract] [Full Text] [Related]

  • 11. PET-derived tumor metrics predict DLBCL response and progression-free survival.
    Islam P, Goldstein J, Flowers CR.
    Leuk Lymphoma; 2019 Aug 25; 60(8):1965-1971. PubMed ID: 30714446
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prognostic Value of Pre-Autologous Stem Cell Transplantation PET/CT in Diffuse Large B-Cell Lymphoma: The Deauville Score Is Prognostically Superior to ΔSUVmax.
    Zhang XY, Song L, Wang PJ, Wang L, Li Y, Wang YY, Shi CL.
    Acta Haematol; 2020 Aug 25; 143(2):124-130. PubMed ID: 31382264
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.